Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 9 Melanoma 4 Neoplasms 3 Multiple Myeloma 3 Skin Neoplasms 2 Polycystic Ovary Syndrome 2 Venous Thromboembolism 1 Triple Negative Breast Neoplasms 1 Thrombocythemia, Essential 1 Stem Cell Transplant Complications 1 Skin Toxicity 1 Resectable Pancreatic Ductal Adenocarcinoma 1 Renal Insufficiency 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Obesity 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Meningioma 1 Lymphoma, Mantle-Cell 1 Lung Neoplasms 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, B-Cell 1 Leukemia 1 Inflammation 1

Interventions

Carboplatin 2 tislelizumab 1 epigallocatechin gallate 1 Tablets 1 Range of Motion, Articular 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy 1 Pravastatin 1 Paclitaxel 1 Lead 1 Fibroblast Growth Factor 7 1 Esophagectomy 1 Cisplatin 1 Amifostine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Deglutition Disorders × Tablets × Clear all

NCT07217938 2026-03-03

TRADstat

Peter MacCallum Cancer Centre, Australia

Phase 2 Recruiting

Deglutition Disorders, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡